Navigation Links
VIVUS Reports Topline Findings From FORTRESS
Date:12/21/2011

NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or CHMP's 120-day questions, the FDA's requests stemming from the end-of-review meeting or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA or CHMP's safety concerns, that the FDA or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will recei
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
2. VIVUS Resubmits Qnexa NDA to the FDA
3. VIVUS Provides Regulatory Update on QNEXA
4. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
5. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
6. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
7. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
8. VIVUS to Present at Three Upcoming Investor Conferences in March
9. VIVUS Provides Regulatory Update on QNEXA NDA
10. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. ... were exposed to high levels of air pollution late in ... U.S. study suggests. Researchers found that of nearly 1,800 ... exposed to the most air pollution during pregnancy were twice ... And exposure during the third trimester, specifically, showed the strongest ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Traveling through ... the measles virus to three others within a four-hour ... spread, a new report shows. "The exposures in ... domestic rather than an international terminal, highlighting the fact ... by Jared Vega, an infectious disease specialist at the ...
(Date:12/19/2014)... Steven Reinberg HealthDay ... If you can,t balance on one leg for at least ... Japanese researchers suggest. Difficulty standing on one leg may ... which means the risk for more serious strokes is high, ... Stroke . "Individuals showing instability while standing on one ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay ... struggle with heart failure, experts say new treatments have ... for these patients. "The present environment for heart ... that will truly remove the term ,failure, from the ...
... Hall Institute scientists have revealed new details about ... system, identifying in the process potential new therapeutic ... Jeff Babon and Professor Nick Nicola, from the ... respectively, study interactions between internal cell signalling proteins ...
... fracture easily. It is a major complication of spinal cord ... A new clinical trial conducted by University of Iowa researchers ... bone through programmed electrical stimulation of the muscle significantly slows ... The focus on quantifying the effective dose of load is ...
... -- In an effort to reduce and eventually eliminate cancer ... Cancer Center at Jefferson has established the Center ... Mitchell, M.D., FACP , a medical oncologist at Thomas ... Medical Oncology in the Department of Medical Oncology at Jefferson ...
... Reporter , THURSDAY, Feb. 16 (HealthDay News) -- A sweetener ... of arsenic, new research suggests. Researchers at Dartmouth College ... found in some infant formulas. Their report appears in the ... Arsenic is a natural element that can contaminate groundwater. As ...
... a free, non-promotional online program designed to support ... chronic pain. This study tested painACTION.com,s ability to ... with chronic migraine headaches. A total of 185 ... were more confident that they could prevent headaches ...
Cached Medicine News:Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Cell signaling discovery provides new hope for blood disorders 2Health News:High doses of 'load' slows loss of bone in spinal cord injury 2Health News:High doses of 'load' slows loss of bone in spinal cord injury 3Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 2Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 3Health News:Arsenic Might Be Found in Some Organic Foods: Study 2Health News:Arsenic Might Be Found in Some Organic Foods: Study 3Health News:painACTION.com improves migraine self-management and reduces migraine-related psychological distress 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: